

Cu-Catalyzed Oxidative Imino Diels-Alder Cyclization: Synthesis of Dihydrofuroquinolines

Vikash Kumar,^a Ashutosh Dey,^a Rohit Kumar Maurya,^a Abhay Kumar Yadav,^a Megha Kumari,^a
Angad Kumar Singh^a and Mahender Khatravath^{a*}

^aDepartment of Chemistry, Central University of South Bihar, SH-7, Gaya Panchanpur Road,
Karhara, Gaya-824236, Bihar, India; E-mail: mkhatravath@cusb.ac.in;
k.mahender666@gmail.com, Angad Kumar Singh (angad@cusb.ac.in)

*Corresponding author: Dr. Mahender Khatravath
Department of Chemistry, Central University of South Bihar, Gaya
E-mail: k.mahender666@gmail.com, mkhatravath@cusb.ac.in.

Supporting information	Page
Experimental Section: General Methods	S ₃
Synthesis Scheme of Dihydrofuroquinolines	S ₄
Synthesis Scheme of Sonogashira Compound (S _{3a-1})	S ₅
Synthesis Scheme of Aldehyde Compound (1a-l)	S ₆
General procedure A, for the synthesis of compound S ₂ from S ₁ .	S ₇ -S ₈
General Procedure B, for the synthesis of compounds S _{3a-1} from S ₂ and S ₄ .	S ₈
General procedure C, for the synthesis of compounds from S _{3a-1} to 1a-l.	S ₈ -S ₉
General procedure D, for the synthesis of compounds 3a-v from 1a-l.	S ₉
General procedure E, for the synthesis of compounds from 3c and 3f to 4a-b.	S ₉ -S ₁₀


Preparation of Sonogashira Cross Coupled Products and Characterization	S ₁₀ -S ₁₃
Preparation of Dihydrofuroquinolines (3a-v) and Characterization	S ₁₄ -S ₂₁
Preparation of quinoline-fused lactones (4a-b) and Characterization	S ₂₁ -S ₂₂
Spectral (¹ H, ¹³ C, and ¹⁹ F) data of Synthesized Compounds	S ₂₃ -S ₆₂
Crystallographic Data	S ₆₃ -S ₆₇

EXPERIMENTAL SECTION

General Methods:


All reactions were carried out in flame-dried glassware under a Nitrogen atmosphere. Thin layer chromatography (TLC) was carried out on aluminium sheets coated with silica gel (60–120 and 100-200 mesh), and the spots were visualized with UV light at 254 nm or alternatively by staining with aqueous basic potassium permanganate or ceric ammonium molybdate. Column chromatography was performed on silica gel (60–120 and 100-200 mesh) using hexanes and ethyl acetate. Commercially available reagents were used as supplied and some of them were distilled before use. ^1H and ^{13}C NMR spectra were recorded in CDCl_3 solvent on, 400 MHz and 500 MHz and 600 MHz NMR spectrometer (Chemical shifts were reported in ppm from tetramethylsilane with the solvent resonance as the internal standard in CDCl_3 solution, unless otherwise noted). Chemical shifts δ and coupling constants J are given in ppm (parts per million) and Hz (hertz) respectively. Chemical shifts are reported relative to residual solvent as an internal standard for ^1H and ^{13}C (CDCl_3 : δ 7.26 ppm for ^1H and 77.0 ppm for ^{13}C). High resolution mass spectra (HRMS) [ESI+] were obtained using either a TOF or a double focusing spectrometer. ACN, DCM, THF and MeOH were dried immediately prior to use according to standard procedures. Acetonitrile, Dichloromethane was distilled under N_2 from CaH_2 . All solvents were removed by evaporation under reduced pressure. Single-crystal X-ray diffraction data were collected on a Rigaku XtaLAB Synergy-I diffractometer using *CrysAlisPro* software, with graphite-monochromated Mo $\text{K}\alpha$ ($\lambda = 0.71073 \text{ \AA}$) and Cu $\text{K}\alpha$ ($\lambda = 1.54184 \text{ \AA}$) radiation at 293 K. The crystal structures were solved using the SHELXL-97 program implemented in OLEX2.0, and refined by full-matrix least-squares procedures on F^2 . Anisotropic displacement parameters were applied to all non-hydrogen atoms. Hydrogen atoms were placed in calculated positions and refined using a riding model with idealized geometries. Structural visualization and analysis were carried out using Mercury software for Windows.

Synthesis scheme for Dihydrofuroquinolines



Scheme S1: Synthetic strategy for the development of the methodology.


Synthesis Scheme of Sonogashira (S_{3a-l})



Scheme S2: List of Sonogashira cross coupled products prepared.


The experimental and spectral data of compounds S_3 - S_{3h} , and S_{3i} is reported in previous reports.¹

Synthesis Scheme of Aldehyde (1a-1l)




Scheme S3: List of aldehyde products synthesized.

General procedure A, for the synthesis of compound **S**₂ from **S**₁.



A stirred solution of diol **S**_{1a} (1 equiv.) in acetonitrile was treated with potassium carbonate (5 equiv.), followed by the careful dropwise addition of propargyl bromide (1.5 equiv.). Then the reaction mixture was stirred at room temperature for 5 h. After completion (monitored by TLC), the mixture was filtered through a celite pad. Next, 50 ml of water is introduced to the reaction mixture, which was then extracted with ethyl acetate three times (3 × 50 ml). The combined organic extracts are washed with brine (50 ml), dried over sodium sulfate, and concentrated under reduced pressure. Finally, the crude product is purified by flash column chromatography, resulting in Compound **S**_{2a} with considerable yield (up to 45%).

Synthesis of (*R*)-2-(prop-2-yn-1-yloxy)propan-1-ol (**S**_{2b}).




Step 1: A stirred solution of (*R*)-1-(*tert*-butyldimethylsilyl)propan-2-ol **S**₄ (20.0 g, 1 equiv.) in anhydrous DMF at 0 °C under nitrogen was treated with sodium hydride (60% dispersion in mineral oil, 3.3 g, 1.2 equiv.) portion wise. After stirring for 30 minutes, propargyl bromide (1.2 equiv., 80 wt% solution in toluene) was added dropwise. The mixture was warmed to room temperature and stirred until complete consumption of the starting material, as confirmed by TLC. The reaction was quenched with saturated aqueous ammonium chloride, diluted with ethyl acetate, and the layers were separated. The organic extracts were washed with brine, dried over sodium sulfate, filtered, and concentrated. This crude product was directly used in the next step without purification.

Step 2: The above crude silyl-protected propargyl ether was dissolved in THF and TBAF (1.0 M solution in THF, 1.2 equiv.) was added dropwise at 0 °C and stirred for 1 hour until deprotection was confirmed by TLC. After quenching with aqueous ammonium chloride and extraction with ethyl acetate, the organic layers were washed, dried, filtered, and concentrated to yield (*R*)-2-(prop-2-yn-1-yloxy)propan-1-ol **S_{2b}** (4.7 g) as a yellow oil in 36% overall yield (over two steps). ¹H NMR (500 MHz, CDCl₃) δ 4.26 (dd, *J* = 15.8, 2.4 Hz, 1H), 4.21 – 4.12 (m, 1H), 3.81 – 3.72 (m, 1H), 3.65 – 3.57 (m, 1H), 3.51 – 3.45 (m, 1H), 1.14 (d, *J* = 6.3 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 80.15, 75.57, 74.35, 66.32, 56.22, 15.63.


Note: Compound **S₄** was synthesized by using previous report.²

General Procedure B, for the synthesis of compounds **S_{3a-l} from **S₂**.**




The stirred solution of compound **S₂** (1 equiv.) in THF (2 mL) was effectively reacted with a variety of substituted iodobenzene derivatives (1.1 equiv.), along with Pd (PPh₃)₂Cl₂ (2 mol%), CuI (4 mol%), and triethylamine (1.5 equiv.) under nitrogen atmosphere. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with saturated NH₄Cl and the organic layer was extracted with ethyl acetate (EtOAc). The combined organic extracts were thoroughly washed with brine (50 mL), dried over sodium sulfate, and then concentrated under reduced pressure. The resulting crude products were purified through flash column chromatography, to afford the desired products **S_{3a-l}** with excellent yield up to 90%.

General procedure C, for the synthesis of compounds from **S_{3a-l} to **1a-l**.**




To a stirred solution of oxalyl chloride (1.2 equiv.) in dichloromethane (5 mL) at -78 °C, DMSO (2.4 equiv.) was added dropwise, and the reaction mixture was allowed to stir at the same temperature for 5 minutes. A solution of alcohol (1 equiv.) in 3 mL dichloromethane was then added to the reaction mixture. After 45 min of stirring, triethylamine (5 equiv.) was added, and after 5 minutes reaction mixture was warmed to ambient temperature for 2 h. The reaction mixture was then diluted with dichloromethane and water and the layers were separated. The organic layer was washed with water, brine, dried over MgSO₄, filtered and concentrated in vacuo. Without further purification, the respective aldehydes were used for further imino Diels- Alder reaction.

General procedure D, for the synthesis of compounds 3a-v from 1a-l.



To the crude solution of aldehyde (1 equiv.) and aniline (1 equiv.) in acetonitrile solvent was added $\text{Cu}(\text{OTf})_2$ (0.05 mol%) and Oxone (1 equiv.) at room temperature. Then, the resulting reaction mixture was allowed to stir at same temperature for 12 h. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with saturated aqueous ammonium chloride solution and was extracted with water and ethyl acetate. The organic layer was then dried over Na_2SO_4 and evaporated under vacuo. The residue was separated by column chromatography using the mixture EtOAc/hexanes (1:2) to afford the desired dihydrofuroquinolines **3a-v**.

General procedure E, for the synthesis of compounds from 3c and 3f to 4a-b




To a solution of dihydrofuroquinoline (0.439 mmol) in benzene was added Pyridinium dichromate (PDC, 0.087 mmol) at room temperature. The resulting suspension was stirred vigorously and a solution of *tertiary* butyl hydroperoxide in decane (5.0-6.0 M solution) was added dropwise over 15 min. The reaction mixture was then stirred further at room temperature for 4 h. After completion of the reaction (monitored by TLC), the reaction mixture was filtered. The resulting crude was purified by column chromatography on silica gel with hexane/ethyl acetate (9:1) to afford the desired oxidized products **4a-b**.

General procedure for the preparation of cross coupled Sonogashira products

The experimental and spectral data of compounds **S_{3a}**, **S_{3b}**, **S_{3c}**, **S_{3e}**, and **S_{3i}** were reported in our previous work.^{12e}


Synthesis of Sonagashira product (S_{3a}-S_{3i})

Synthesis of-2-((3-phenylprop-2-yn-1-yl) oxy) ethan-1-ol (S_{3a}).




Following the general procedure **B**, **S₂** (1.00 gm, 10.00 mmol) in THF was allowed to react with iodobenzene (1.24 ml, 11.00 mmol) in the presence of Pd(PPh₃)₂Cl₂ (140 mg, 0.02 mmol), CuI (38 mg, 0.2 mmol), Et₃N (2.16 ml, 15.00 mmol) to afford compound **S_{3a}** in 85% yield (1.5 g); Yellowish oil; ¹H NMR (400 MHz, CDCl₃) δ 7.48 – 7.42 (m, 2H), 7.34 – 7.28 (m, 3H), 4.43 (s, 1H), 3.84 – 3.78 (m, *J* = 3.5 Hz, 2H), 3.72 (dd, 2H), 2.26 (bs, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 131.78, 128.57, 128.33, 122.46, 86.55, 84.79, 71.26, 61.79, 59.22.

Synthesis of-2-((3-(*o*-tolyl) prop-2-yn-1-yl) oxy) ethan-1-ol (S_{3b})




Following the general procedure **B**, **S₂** (1g, 10.0 mmol) in THF was allowed to react with 2-iodotoluene (1.41 ml, 11.00 mmol) in the presence of Pd(PPh₃)₂Cl₂ (140 mg, 0.02 mmol), CuI (38 mg, 0.02 mmol), Et₃N (2.16 ml, 15.00 mmol) to afford compound **S_{3b}** in 65% yield (1.25 g); Yellowish oil; ¹H NMR (400 MHz, CDCl₃) δ 7.41 (d, *J* = 7.4 Hz, 1H), 7.26 – 7.17 (m, 2H), 7.13 (ddd, *J* = 6.9, 4.6, 1.6 Hz, 1H), 4.48 (s, 2H), 3.80 (d, *J* = 7.0 Hz, 2H), 3.77 – 3.72 (m, 2H), 2.44 (s, 3H), 2.13 (bs, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 140.30, 132.15, 129.46, 128.56, 125.56, 122.26, 88.60, 85.47, 71.11, 61.84, 59.30, 20.73.

Synthesis of- 2-((3-(*m*-tolyl) prop-2-yn-1-yl) oxy) ethan-1-ol (S_{3c}).




Following the general procedure **B**, **S₂** (1.0 g, 10.00 mmol) in THF was allowed to react with 4-iodotoluene (1.41 ml, 11.00 mmol) in the presence of Pd(PPh₃)₂Cl₂ (140 mg, 0.02 mmol), CuI (38 mg, 0.02 mmol), Et₃N (2.16 ml, 15.00 mmol) to afford compound **S_{3c}** in 72% yield (1.37 g); Yellowish oil; ¹H NMR (400 MHz, CDCl₃) δ 7.27 (s, 1H), 7.25 (d, *J* = 8.0 Hz, 1H), 7.20 (t, *J* = 7.5 Hz, 1H), 7.14 (d, *J* = 7.5 Hz, 1H), 4.43 (s, 2H), 3.82 – 3.79 (m, 2H), 3.74 – 3.70 (m, 2H), 2.32 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 138.03, 132.35, 129.45, 128.83, 128.22, 122.25, 86.74, 84.40, 71.18, 61.84, 59.23, 21.19.

Synthesis of-2-((3-(*p*-tolyl) prop-2-yn-1-yl) oxy) ethan-1-ol (**S_{3d}**).




Following the general procedure **B**, **S₂** (1.0 g, 10.00 mmol) in THF was allowed to react with 4-iodotoluene (1.41 ml, 11.00 mmol) in the presence of Pd(PPh₃)₂Cl₂ (140 mg, 0.02 mmol), CuI (38 mg, 0.02 mmol), Et₃N (2.16 ml, 15.00 mmol) to afford compound **S_{3d}** in 72% yield (1.37 g); Yellowish oil; ¹H NMR (400 MHz, CDCl₃) δ 7.34 (d, *J* = 8.1 Hz, 2H), 7.12 (d, *J* = 7.9 Hz, 2H), 4.42 (s, 2H), 3.83 – 3.78 (m, 2H), 3.74 – 3.70 (m, 2H), 2.34 (s, 3H), 2.22 (bs, *J* = 20.4, 6.7 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 138.72, 131.68, 129.09, 119.36, 86.69, 84.07, 71.20, 61.82, 59.27, 21.49.

Synthesis of-2-((3-(2-methoxyphenyl) prop-2-yn-1-yl) oxy) ethan-1-ol (**S_{3e}**).



Following the general procedure **B**, **S₂** (1.00g, 10.00 mmol) in THF was allowed to react with 2-iodo methoxybenzene (1.51 ml, 11.00 mmol) in the presence of Pd(PPh₃)₂Cl₂ (140 mg, 0.02 mmol), CuI (38 mg, 0.02 mmol), Et₃N (2.16 ml, 15.00 mmol) to afford compound **S_{3e}** in 62% yield (1.29 g); Yellowish oil; ¹H NMR (400 MHz, CDCl₃) δ 7.34 (dd, *J* = 7.6, 1.7 Hz, 1H), 7.26 – 7.21 (m, 1H), 6.86 – 6.79 (m, 2H), 4.41 (s, 2H), 3.81 (s, 3H), 3.76 – 3.73 (m, 2H), 3.70 – 3.66 (m, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 160.08, 133.72, 130.04, 120.46, 111.57, 110.58, 89.03, 82.87, 71.29, 61.88, 59.44, 55.77.


Synthesis of-2-((3-(4-methoxyphenyl)prop-2-yn-1-yl)oxy)ethan-1-ol (**S_{3f}**).



Following the general procedure **B**, **S₂** (1 g, 10.00 mmol) in THF was allowed to react with 2-iodo methoxybenzene (1.51 ml, 11.00 mmol) in the presence of Pd(PPh₃)₂Cl₂ (140 mg, 0.02 mmol), CuI (38 mg, 0.02 mmol), Et₃N (2.16 ml, 15.00 mmol) to afford compound **S_{3f}** in 62% yield (1.29 g);

Yellowish oil; ^1H NMR (400 MHz, CDCl_3) δ 7.32 (t, $J = 5.7$ Hz, 2H), 6.77 (t, $J = 5.7$ Hz, 2H), 4.35 (s, 2H), 3.74 (s, 3H), 3.72 (s, 2H), 3.67 – 3.62 (m, 2H). ^{13}C NMR (101 MHz, CDCl_3) δ 159.81, 133.28, 114.53, 113.95, 86.49, 83.37, 71.14, 61.85, 59.31, 55.29, 29.70.


Synthesis of methyl 2-(3-(2-hydroxyethoxy)prop-1-yn-1-yl)benzoate (S_{3g}).



Following the general procedure **B**, S_2 (1 g, 10.00 mmol) in THF was allowed to react with Methyl-4-iodobenzoate (2.8 ml, 11.00 mmol) in the presence of $\text{Pd}(\text{PPh}_3)_2\text{Cl}_2$ (140 mg, 0.02 mmol), CuI (38 mg, 0.02 mmol), Et_3N (2.16 ml, 15.00 mmol) to afford compound S_{3g} in 61% yield (1.43 g);

Yellowish oil; ^1H NMR (400 MHz, CDCl_3) δ 7.96 (d, $J = 8.3$ Hz, 2H), 7.47 (d, $J = 8.3$ Hz, 2H), 4.43 (s, 2H), 3.89 (s, 3H), 3.82 – 3.77 (m, 2H), 3.73 – 3.68 (m, 2H). ^{13}C NMR (101 MHz, CDCl_3) δ 162.33, 153.44, 136.79, 135.03, 129.81, 128.56, 125.79, 120.85, 104.37, 72.55, 69.38, 61.89.


Synthesis of 2-((3-(thiophen-2-yl)prop-2-yn-1-yl)oxy)ethan-1-ol (S_{3h}).



Following the general procedure **B**, S_2 (1 g, 10.00 mmol) in THF was allowed to react with 3-iodo nitrobenzene (2.7 g, 11.00 mmol) in the presence of $\text{Pd}(\text{PPh}_3)_2\text{Cl}_2$ (140 mg, 0.02 mmol), CuI (38 mg, 0.02 mmol), Et_3N (2.16 ml, 15.00 mmol) to afford compound S_{3h} in 73% yield (1.3 g); Yellowish oil; ^1H

NMR (400 MHz, CDCl_3) δ 7.21 – 7.18 (m, 1H), 7.15 (dt, $J = 5.1, 2.5$ Hz, 1H), 6.90 (dd, $J = 5.2, 3.6$ Hz, 1H), 4.37 (s, 2H), 3.72 (d, $J = 4.3$ Hz, 2H), 3.66 – 3.61 (m, 2H). ^{13}C NMR (101 MHz, CDCl_3) δ 132.56, 127.51, 126.98, 122.34, 88.81, 79.83, 71.28, 61.90, 59.28.


Synthesis of methyl 2-(3-(2-hydroxyethoxy) prop-1-yn-1-yl) benzoate (S_{3i}).



Following the general procedure **B**, S_2 (1 g, 10.00 mmol) in THF was allowed to react with Methyl-4-iodobenzoate (2.8 ml, 11.00 mmol) in the presence of $\text{Pd}(\text{PPh}_3)_2\text{Cl}_2$ (140 mg, 0.02 mmol), CuI (38 mg, 0.02 mmol), Et_3N (2.16 ml, 15.00 mmol) to afford compound S_{3i} in 61%

yield (1.43 g); Yellowish oil; ^1H NMR (400 MHz, CDCl_3) δ 7.96 (d, $J = 8.3$ Hz, 2H), 7.47 (d, $J = 8.3$ Hz, 2H), 4.43 (s, 2H), 3.89 (s, 3H), 3.82 – 3.77 (m, 2H), 3.73 – 3.68 (m, 2H). ^{13}C NMR (101 MHz, CDCl_3) δ 166.46, 131.64, 129.82, 129.46, 127.14, 87.87, 85.72, 71.41, 61.72, 59.11, 52.24.


Synthesis of (*R*)-2-((3-phenylprop-2-yn-1-yl)oxy)propan-1-ol (S_{3j}).



Following the general procedure **B**, **S₂** (0.5 g, 4.38 mmol) in THF was allowed to react with iodobenzene (0.98 g, 4.81 mmol) in the presence of Pd(PPh₃)₂Cl₂ (56 mg, 0.02 mmol), CuI (16 mg, 0.02 mmol), Et₃N (0.9 ml, 6.57 mmol) to afford compound **S_{3j}** in 61% yield (0.40 g); Yellowish oil;

¹H NMR (500 MHz, CDCl₃) δ 7.49 – 7.39 (m, 2H), 7.33 – 7.28 (m, 3H), 4.49 (d, *J* = 15.8 Hz, 1H), 4.39 (d, *J* = 15.9 Hz, 1H), 3.89 – 3.80 (m, 1H), 3.64 (d, *J* = 3.3 Hz, 1H), 3.52 (dd, *J* = 11.6, 7.0 Hz, 1H), 1.19 (d, *J* = 6.3 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 131.86, 131.83, 128.64, 128.60, 128.40, 122.59, 86.60, 86.18, 85.43, 84.87, 75.69, 75.60, 66.55, 66.40, 59.36, 57.07, 29.78, 18.75, 17.78, 15.80.


Synthesis of methyl (*R*)-4-(3-((1-hydroxypropan-2-yl)oxy)prop-1-yn-1-yl)benzoate (**S_{3k}**).



Following the general procedure **B**, **S₂** (0.5 g, 4.38 mmol) in THF was allowed to react with Methyl-4-iodobenzoate (1.2 g, 4.81 mmol) in the presence of Pd(PPh₃)₂Cl₂ (56 mg, 0.02 mmol), CuI (16 mg, 0.02 mmol), Et₃N (0.9 ml, 6.57 mmol) to afford compound **S_{3k}** in

68% yield (0.73 g); Yellowish oil; ¹H NMR (500 MHz, CDCl₃) δ 7.96 (d, 2H), 7.47 (d, 2H), 4.49 (d, *J* = 16.0 Hz, 1H), 4.43 – 4.37 (m, 1H), 3.89 (s, 3H), 3.86 – 3.78 (m, 1H), 3.64 (dd, *J* = 11.6, 3.3 Hz, 1H), 3.53 (d, *J* = 7.0 Hz, 1H), 1.18 (d, *J* = 6.3 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 166.55, 131.72, 129.89, 129.55, 127.27, 88.52, 85.38, 75.79, 66.37, 59.27, 56.98, 52.32, 18.79, 15.77.

Synthesis of (*R*)-2-((3-((thiophen-2-yl)prop-2-yn-1-yl)oxy)propan-1-ol (**S_{3l}**).




Following the general procedure **B**, **S₂** (0.5 g, 4.38 mmol) in THF was allowed to react with 2-iodothiophene (1.0 g, 4.81 mmol) in the presence of Pd(PPh₃)₂Cl₂ (56 mg, 0.02 mmol), CuI (16 mg, 0.02 mmol), Et₃N (0.9 ml, 6.57 mmol) to afford compound **S_{3l}** in 45% yield (0.37 g); Yellowish oil;

¹H NMR (500 MHz, CDCl₃) δ 7.24 (d, *J* = 1.7 Hz, 1H), 7.21 (d, *J* = 1.2 Hz, 1H), 6.95 (dd, *J* = 5.1, 3.6 Hz, 1H), 4.49 (d, *J* = 16.1 Hz, 1H), 4.39 (d, *J* = 16.0 Hz, 1H), 3.86 – 3.76 (m, 1H), 3.63 (dd, *J* = 11.7, 3.3 Hz, 1H), 3.51 (dd, *J* = 11.6, 7.0 Hz, 1H), 1.17 (d, *J* = 6.3 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 132.58, 127.51, 127.03, 122.50, 89.43, 79.44, 75.64, 66.37, 57.11, 15.77.


Synthesis of dihydrofuroquinoline (**3a-v**)

Synthesis of 9-phenyl-1,3-dihydrofuro[3,4-*b*]quinoline (**3a**).




Following the general procedure **D**, **1a** (150 mg, 0.86 mmol) in acetonitrile was allowed to react with aniline (**2a**), (0.078 ml, 0.86 mmol) in the presence of $\text{Cu}(\text{OTf})_2$ (15.56 mg, 0.043 mmol), Oxone (264.63 mg, 0.86 mmol), to afford compound **3a** in 72% yield (207 mg); White solid; mp 209 °C; ^1H NMR (500 MHz, CDCl_3) δ 8.10 (d, $J = 8.2$ Hz, 1H), 7.76 – 7.73 (m, 1H), 7.69 (ddd, $J = 8.3, 6.9, 1.3$ Hz, 1H), 7.55 – 7.50 (m, 2H), 7.49 (dt, $J = 5.7, 2.3$ Hz, 1H), 7.47 – 7.43 (m, 1H), 7.38 – 7.36 (m, 2H), 5.23 (s, 2H), 5.12 (s, 2H). ^{13}C NMR (126 MHz, CDCl_3) δ 162.30, 148.82, 141.43, 135.64, 129.31, 129.19, 128.96, 129.03, 128.93, 128.76, 126.46, 126.15, 125.82, 73.16, 71.90; HRMS (ESI): m/z calcd for $\text{C}_{17}\text{H}_{14}\text{NO}$ $[\text{M}+\text{H}]^+$; 248.1075, found: 248.1075.


Synthesis of 5-methyl-9-phenyl-1,3-dihydrofuro[3,4-*b*]quinoline (**3b**).

 Following the general procedure **D**, **1i** (200 mg, 1.06 mmol) in acetonitrile was allowed to react with *ortho*-toluidine (64 mg, 1.06 mmol) in the presence of $\text{Cu}(\text{OTf})_2$ (19 mg, 0.05 mmol), Oxone (325 mg, 1.06 mmol), to afford compound **3b** in 47% yield (132 mg); Yellow Solid; mp 133 °C; ^1H NMR (500 MHz, CDCl_3) δ 7.57 (d, 1H), 7.56 – 7.45 (m, 4H), 7.38 – 7.30 (m, 3H), 5.27 (s, 2H), 5.12 (s, 2H), 2.84 (s, 3H). ^{13}C NMR (126 MHz, CDCl_3) δ 161.12, 136.96, 136.15, 129.60, 128.96, 128.87, 128.67, 128.61, 126.11, 125.97, 123.84, 73.41, 71.90, 18.72; HRMS (ESI): m/z calcd for $\text{C}_{18}\text{H}_{16}\text{NO}$ $[\text{M}+\text{H}]^+$; 262.1231, found: 262.1233.

Synthesis of 5-bromo-9-phenyl-1,3-dihydrofuro[3,4-*b*]quinoline (**3c**).


 Following the general procedure **D**, **1a** (150 mg, 0.86 mmol) in acetonitrile was allowed to react with 2-Bromo aniline (**2b**), (148 mg, 0.86 mmol) in the presence of $\text{Cu}(\text{OTf})_2$ (15.56 mg, 0.043 mmol), Oxone (264.63 mg, 0.86 mmol), to afford compound **3c** in 75% yield (210 mg); White solid; mp 271 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.04 (dd, $J = 7.4, 1.0$ Hz, 1H), 7.72 (dd, $J = 8.4, 1.1$ Hz, 1H), 7.58 – 7.48 (m, 3H), 7.36 (dd, $J = 7.8, 1.6$ Hz, 2H), 7.30 (t, 1H), 5.32 (s, 2H), 5.13 (s, 2H). ^{13}C NMR (101 MHz, CDCl_3) δ 163.53, 145.97, 141.86, 135.24, 133.02, 130.04, 128.96, 128.90, 128.82, 127.76, 126.54, 125.77, 124.68, 73.31, 71.66; HRMS (ESI): m/z calcd. for $\text{C}_{17}\text{H}_{13}\text{NOBr}$ $[\text{M}+\text{H}]^+$; 326.0180, found: 326.0183.

Synthesis of 5-iodo-9-phenyl-1,3-dihydrofuro[3,4-*b*] quinoline (**3d**).

 Following the general procedure **D**, **1a** (150 mg, 0.86 mmol) in acetonitrile was allowed to react with 2-iodo aniline (**2c**), (188.77 mg, 0.86 mmol) in the presence of $\text{Cu}(\text{OTf})_2$ (15.56 mg, 0.043 mmol), Oxone (264.63 mg, 0.86 mmol), to afford


compound **3d** in 80% yield (260 mg); White solid; mp 143 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.31 (d, *J* = 7.2 Hz, 1H), 7.73 (d, *J* = 8.3 Hz, 1H), 7.58 – 7.47 (m, 3H), 7.35 (d, *J* = 6.6 Hz, 2H), 7.16 (t, *J* = 7.8 Hz, 1H), 5.31 (s, 2H), 5.12 (s, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 163.65, 147.69, 141.87, 139.93, 135.15, 130.02, 128.95, 128.85, 127.35, 127.01, 126.72, 103.18, 73.18, 71.67; HRMS (ESI): *m/z* calcd for C₁₇H₁₃NOI [M+H]⁺; 374.0041, found: 374.0041.

Synthesis of 5-iodo-7-methyl-9-phenyl-1,3-dihydrofuro[3,4-*b*]quinoline (**3e**).




Following the general procedure **D**, **3a** (150 mg, 0.86 mmol) in acetonitrile was allowed to react with 2-Iodo-4-methylaniline (**2d**), (200.84 mg, 0.86 mmol) in the presence of Cu(OTf)₂ (15.56 mg, 0.043 mmol), Oxone (264.63 mg, 0.086 mmol), to afford compound **3e** in 78% yield (262 mg); White solid; mp 133 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.19 (d, *J* = 1.5 Hz, 1H), 7.58 – 7.50 (m, 3H), 7.46 (s, 1H), 7.34 (dd, *J* = 7.8, 1.5 Hz, 2H), 5.30 (s, 2H), 5.10 (s, 2H), 2.39 (s, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 157.94, 141.57, 137.19, 136.48, 132.78, 130.66, 125.29, 124.23, 124.13, 124.03, 122.01, 120.98, 98.14, 68.44, 66.99, 16.40; HRMS (ESI): *m/z* calcd for C₁₈H₁₅INO [M+H]⁺; 388.0198, found: 388.0199.

Synthesis of 5-iodo-9-phenyl-7-(trifluoromethyl)-1,3-dihydrofuro[3,4-*b*]quinoline (**3f**).



Following the general procedure **D**, **1a** (150 mg, 0.86 mmol) in acetonitrile was allowed to react with 2-Iodo-4-(trifluoromethyl)aniline (**2e**), (247.4 mg, 0.086 mmol) in the presence of Cu(OTf)₂ (15.56 mg, 0.043 mmol), Oxone (264.63 mg, 0.86 mmol), to afford compound **3f** in 55% yield (210 mg); White solid; mp 168 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.48 (s, 1H), 8.04 (s, 1H), 7.64 – 7.51 (m, 3H), 7.36 (d, *J* = 7.3 Hz, 2H), 5.33 (s, 2H), 5.15 (s, 2H). ¹⁹F NMR (471 MHz, CDCl₃) δ -62.07. ¹³C NMR (101 MHz, CDCl₃) δ 166.06, 148.94, 142.79, 135.46 (q, 3.2 Hz) 132.77 (q, 273.0 Hz), 129.41, 129.08 (q, 35.6 Hz) 128.75, 125.75, 124.44 (q, 4.2 Hz) 124.32, 121.61, 104.14, 73.16, 71.58; HRMS (ESI): *m/z* calcd for C₁₈H₁₂F₃INO [M+H]⁺; 441.9915, found: 441.9917.


Synthesis of 5-bromo-9-(*o*-tolyl)-1,3-dihydrofuro[3,4-*b*]quinoline (**3g**).



Following the general procedure **D**, **1b** (125 mg, 0.66 mmol) in acetonitrile was allowed to react with 2-Bromo aniline (**2b**), (115.53 mg, 0.66 mmol) in the presence of Cu(OTf)₂ (12.0 mg, 0.033 mmol), Oxone (203.8 mg, 0.66 mmol), to afford compound **3g** in 55% yield (125 mg); White solid; mp 165 °C; ¹H NMR


(400 MHz, CDCl₃) δ 8.04 (dd, $J = 7.4, 1.3$ Hz, 1H), 7.43 – 7.36 (m, 3H), 7.33 (dd, $J = 11.5, 4.3$ Hz, 1H), 7.29 (d, $J = 7.5$ Hz, 1H), 7.14 (d, $J = 6.8$ Hz, 1H), 5.36 (s, 2H), 5.07 (d, $J = 13.9$ Hz, 1H), 4.93 (d, $J = 13.9$ Hz, 1H), 1.98 (s, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 163.72, 145.83, 141.88, 135.68, 134.71, 133.17, 130.70, 130.42, 129.10, 128.52, 128.09, 126.79, 126.44, 125.65, 124.80, 73.40, 71.67, 19.68; HRMS (ESI): m/z calcd for C₁₈H₁₅NOBr [M+H]⁺; 340.0337, found: 340.0332.

Synthesis of 5-iodo-9-(*o*-tolyl)-1,3-dihydrofuro[3,4-*b*]quinoline (3h).




Following the general procedure **D**, **1b** (150 mg, 0.79 mmol) in acetonitrile was allowed to react with 2-Iodo aniline (**2c**), (174.54 mg, 0.79 mmol) in the presence of Cu(OTf)₂ (14.4 mg, 0.039 mmol), Oxone (244.68 mg, 0.79 mmol), to afford compound **3h** in 60% yield (155 mg); White solid; mp 151 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.32 (dd, $J = 7.3, 1.1$ Hz, 1H), 7.45 – 7.39 (m, 2H), 7.39 – 7.31 (m, 2H), 7.17 – 7.11 (m, 2H), 5.35 (s, 2H), 5.06 (d, $J = 13.9$ Hz, 1H), 4.93 (d, $J = 13.9$ Hz, 1H), 1.97 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 163.75, 147.37, 141.98, 140.09, 135.63, 134.49, 130.61, 130.37, 129.01, 128.46, 127.56, 127.30, 126.55, 126.36, 102.99, 73.21, 71.60, 19.64; HRMS (ESI): m/z calcd. for C₁₈H₁₅NOI [M+H]⁺; 388.0198, found: 388.0193.

Synthesis of 5-bromo-9-(*p*-tolyl)-1,3-dihydrofuro[3,4-*b*]quinoline (3i).



Following the general procedure **D**, **3c** (250 mg, 1.33 mmol) in acetonitrile was allowed to react with 2-Bromo aniline (**2b**), (228.58 mg, 1.33 mmol) in the presence of Cu(OTf)₂ (23.8 mg, 0.066 mmol), Oxone (408 mg, 1.33 mmol), to afford compound **3i** in 62% yield (280 mg); Pale-yellow solid; mp 192 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.03 (dd, $J = 7.4, 1.2$ Hz, 1H), 7.76 (dd, $J = 8.4, 1.2$ Hz, 1H), 7.35 (d, $J = 7.9$ Hz, 2H), 7.30 (t, $J = 9.9, 6.0$ Hz, 1H), 7.26 (d, $J = 7.5$ Hz, 3H), 5.33 (s, 2H), 5.14 (s, 2H), 2.47 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 163.46, 142.22, 138.94, 133.06, 132.15, 130.10, 129.65, 128.76, 127.92, 126.50, 125.88, 73.33, 71.74, 21.40; HRMS (ESI): m/z calcd. for C₁₈H₁₅NOBr [M+H]⁺; 340.0337, found: 340.0332.


Synthesis of 5-iodo-7-methyl-9-(*m*-tolyl)-1,3-dihydrofuro[3,4-*b*]quinoline (3j).



Following the general procedure **D**, **1d** (200 mg, 1.15 mmol) in acetonitrile was allowed to react with 2-iodo-4-methylaniline (**2d**), (267.8 gm, 1.15 mmol) in the presence of Cu(OTf)₂ (20.74 mg, 0.57 mmol), Oxone (352.8 mg, 1.15 mmol), to afford compound **3j** in 65% yield (277 mg); Yellowish


oil; ^1H NMR (400 MHz, CDCl_3) δ 8.11 (d, $J = 1.7$ Hz, 1H), 7.39 (dd, $J = 5.5, 0.8$ Hz, 1H), 7.34 (d, $J = 8.1$ Hz, 1H), 7.24 (d, $J = 7.5$ Hz, 1H), 7.06 (d, $J = 7.3$ Hz, 2H), 5.23 (s, 2H), 5.02 (s, 2H), 2.37 (s, 3H), 2.32 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 162.57, 146.03, 142.01, 141.69, 138.73, 137.51, 135.24, 130.05, 129.53, 129.29, 128.82, 126.87, 125.89, 125.81, 102.44, 73.15, 71.73, 21.57, 21.14; HRMS (ESI): m/z calcd for $\text{C}_{19}\text{H}_{17}\text{NOI}$ $[\text{M}+\text{H}]^+$; 402.0354, found: 402.0349.

Synthesis of 5-iodo-9-(2-methoxyphenyl)-7-methyl-1,3-dihydrofuro[3,4-*b*]quinoline (3k).




Following the general procedure **D**, **1e** (150 mg, 0.73 mmol) in acetonitrile was allowed to react with 2-iodo-4-methylaniline (**2d**), (171.3 mg, 0.73 mmol) in the presence of $\text{Cu}(\text{OTf})_2$ (13.27 mg, 0.036 mmol), Oxone (225.7 mg, 0.73 mmol), to afford compound **3k** in 60% yield (185 mg); Brownish yellow solid; mp 191 $^\circ\text{C}$; ^1H NMR (400 MHz, CDCl_3) δ 7.49 (t, $J = 7.8$ Hz, 1H), 7.32 (s, 1H), 7.17 (d, $J = 7.3$ Hz, 1H), 7.09 (dd, $J = 13.4, 7.8$ Hz, 2H), 5.29 (s, 2H), 5.01 (d, $J = 10.6$ Hz, 2H), 3.73 (s, 3H), 2.38 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 162.44, 156.53, 146.14, 141.66, 138.10, 137.16, 130.98, 130.67, 130.39, 127.22, 125.78, 123.65, 120.81, 111.40, 102.74, 73.15, 71.95, 55.50, 21.07; HRMS (ESI): m/z calcd for $\text{C}_{19}\text{H}_{17}\text{INO}_2$ $[\text{M}+\text{H}]^+$; 418.0304, found: 418.0585.

Synthesis of 9-(2-methoxyphenyl)-1,3-dihydrofuro[3,4-*b*]quinoline-7-carbonitrile (3l).



Following the general procedure **D**, **1e** (150 mg, 0.73 mmol) in acetonitrile was allowed to react with 4-aminobenzonitrile (**2f**), (86.7 mg, 0.73 mmol) in the presence of $\text{Cu}(\text{OTf})_2$ (13.24 mg, 0.036 mmol), Oxone (225.7 mg, 0.73 mmol), to afford compound **3l** in 68% yield (151mg); White solid; mp 174 $^\circ\text{C}$; ^1H NMR (400 MHz, CDCl_3) δ 8.17 (d, $J = 8.7$ Hz, 1H), 7.99 (d, $J = 1.4$ Hz, 1H), 7.82 (dd, $J = 8.7, 1.6$ Hz, 1H), 7.58 – 7.51 (m, 1H), 7.18 (dd, $J = 7.4, 2.0$ Hz, 1H), 7.14 (dd, $J = 13.0, 7.8$ Hz, 2H), 5.26 (s, 2H), 5.07 (s, 2H), 3.76 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 165.62, 156.40, 149.73, 138.90, 133.82, 132.54, 131.97, 131.18, 130.56, 130.48, 129.70, 126.39, 121.12, 114.43, 111.58, 109.70, 73.08, 71.91, 55.50; HRMS (ESI): m/z calcd for $\text{C}_{19}\text{H}_{15}\text{N}_2\text{O}_2$ $[\text{M}+\text{H}]^+$; 303.1133, found: 303.1128.


Synthesis of 5-iodo-9-(4-methoxyphenyl)-7-(trifluoromethyl)-1,3-dihydrofuro[3,4-*b*]quinoline (3m).



Following the general procedure **D**, **1f** (150 mg, 0.73 mmol) in acetonitrile was allowed to react with 2-iodo-4-(trifluoromethyl)aniline (**2e**), (210.9 gm,


0.73 mmol) in the presence of Cu(OTf)₂ (13.24 mg, 0.036 mmol), Oxone (225.7 mg, 0.73 mmol), to afford compound **3m** in 45% yield (157 mg); White solid; mp 97 °C; ¹H NMR (500 MHz,) δ 8.46 (d, *J* = 2.4 Hz, 2H), 8.11 – 8.05 (m, 2H), 7.32 – 7.22 (m 1H), 7.11 – 7.03 (m, 1H), 5.31 (s, 2H), 5.16 (s, 2H), 3.91 (s, 3H). ¹⁹F NMR (471 MHz, CDCl₃) δ -62.02. ¹³C NMR (126 MHz, CDCl₃) δ 166.04, 160.41, 142.80, 135.47, 135.44 (q, 3.5 Hz) 131.44 (q, 270 Hz) 130.30, 128.84 (q, 32 Hz) 126.14, 126.05, 124.68, (4.2 Hz) 124.64, 114.78, 104.15, 73.29, 71.81, 55.53.; HRMS (ESI): *m/z* calcd for C₁₉H₁₄F₃INO₂ [M+H]⁺; 472.0021, found: 472.0244.

Synthesis of 5-iodo-7-methyl-9-(thiophen-2-yl)-1,3-dihydrofuro[3,4-*b*]quinoline (**3n**).




Following the general procedure **D**, **1g** (150 mg, 0.83 mmol) in acetonitrile was allowed to react with 2-iodo-4-methylaniline (**2d**), (194 mg, 0.83 mmol) in the presence of Cu(OTf)₂ (15.04 mg, 0.04 mmol), Oxone (255.83 mg, 0.83 mmol), to afford compound **3n** in 58% yield (190 mg); Pale yellow solid; mp 190 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.20 (s, 1H), 7.82 (s, 1H), 7.57 (d, *J* = 5.0 Hz, 1H), 7.28 – 7.23 (m, 1H), 7.21 (d, *J* = 3.3 Hz, 1H), 5.28 (s, 2H), 5.24 (s, 2H), 2.44 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 162.53, 146.34, 142.06, 137.81, 135.12, 134.16, 130.84, 129.18, 127.74, 127.63, 126.84, 125.56, 102.88, 73.21, 72.22; HRMS (ESI): *m/z* calcd for C₁₆H₁₃INOS [M+H]⁺; 393.9762, found: 393.9995.

Synthesis of methyl 2-(5-iodo-1,3-dihydrofuro[3,4-*b*] quinolin-9-yl) benzoate (**3o**).



Following the general procedure **D**, **1h** (300 mg, 1.29 mmol) in acetonitrile was allowed to react with 2-iodoaniline (**2c**), (283.19 mg, 1.29 mmol) in the presence of Cu(OTf)₂ (15.04 mg, 0.04 mmol), Oxone (397.0 mg, 1.29 mmol), to afford compound **3o** in 62% yield (326 mg); Greyish black oil; ¹H NMR (500 MHz, CDCl₃) δ 8.30 – 8.26 (m, 1H), 8.18 – 8.14 (m, 1H), 7.69 – 7.64 (m, 1H), 7.62 – 7.57 (m, 1H), 7.34 – 7.31 (m 1H), 7.24 – 7.22 (m, 1H), 7.11 – 7.06 (m, 1H), 5.31 (s, 2H), 4.96 (q, *J* = 13.6 Hz, 2H), 3.50 (s, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 166.35, 163.44, 147.29, 142.10, 139.82, 136.36, 132.79, 131.17, 130.29, 129.88, 129.66, 129.13, 127.38, 126.18, 103.35, 73.26, 71.58, 52.25, 29.77; HRMS (ESI): *m/z* calcd for C₁₉H₁₅INO₃ [M+H]⁺; 432.0096, found: 432.0099.


Synthesis of methyl 2-(5-iodo-7-methyl-1,3-dihydrofuro[3,4-*b*]quinolin-9-yl) benzoate **3p**.



Following the general procedure **D**, **1h** (300 mg, 1.29 mmol) in acetonitrile was allowed to react with 2-iodo-4-methylaniline (**2d**), (300.57 mg, 1.29


mmol) in the presence of Cu(OTf)₂ (15.04 mg, 0.04 mmol), Oxone (397.0 mg, 1.29 mmol), to afford compound **3p** in 65% yield (380 mg); Yellowish liquid; ¹H NMR (500 MHz, CDCl₃) δ 8.18 – 8.13 (m, 2H), 7.70 – 7.64 (m, 1H), 7.62 – 7.57 (m, 1H), 7.24 – 7.20 (m, 1H), 7.05 (s, 1H), 5.30 – 5.27 (m, 2H), 4.91 (t, *J* = 6.6 Hz, 2H), 3.51 (s, 3H), 2.33 (s, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 166.42, 162.39, 158.82, 145.91, 141.82, 141.38, 139.23, 137.49, 136.54, 132.77, 131.17, 130.35, 130.07, 129.83, 129.59, 129.03, 126.97, 125.22, 122.11, 103.03, 73.21, 71.60, 52.24, 29.77, 21.12; HRMS (ESI): *m/z* calcd for C₂₀H₁₇INO₃ [M+H]⁺; 446.0253, found: 446.0484.

Synthesis of methyl 4-(7-cyano-1,3-dihydrofuro[3,4-*b*]quinolin-9-yl)benzoate (**3q**).




Following the general procedure **D**, **1i** (300 mg, 1.29 mmol) in acetonitrile was allowed to react with 4-aminobenzonitrile (**2f**), (152.22 mg, 1.29 mmol) in the presence of Cu(OTf)₂ (15.04 mg, 0.04 mmol), Oxone (397.0 mg, 1.29 mmol), to afford compound **3q** in 61% yield (220 mg); Yellowish oil; ¹H NMR (500 MHz, CDCl₃) δ 8.27 – 8.24 (m, 2H), 8.20 (d, *J* = 8.7 Hz, 1H), 8.04 (d, *J* = 1.6 Hz, 1H), 7.86 (dd, *J* = 8.7, 1.8 Hz, 1H), 7.46 – 7.43 (m, 2H), 5.25 (s, 2H), 5.13 (s, 2H), 3.99 (s, *J* = 2.5 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 166.30, 165.88, 138.65, 131.79, 131.73, 131.36, 130.89, 130.61, 130.34, 129.55, 128.94, 118.56, 110.58, 73.08, 71.48, 52.59, 29.77; HRMS (ESI): *m/z* calcd for C₂₀H₁₅N₂O₃ [M+H]⁺; 331.1082, found: 331.1082.

Synthesis of (*R*)-5-iodo-3-methyl-9-phenyl-1,3-dihydrofuro[3,4-*b*]quinoline **3r**.



Following the general procedure **D**, **1i** (250 mg, 1.32 mmol) in acetonitrile was allowed to react with 2-Iodo aniline (**2c**) (288 mg, 1.32 mmol) in the presence of Cu(OTf)₂ (22 mg, 0.06 mmol), Oxone (405.0 mg, 1.32 mmol), to afford compound **3r** in 41% yield (135 mg); Yellowish oil; ¹H NMR (500 MHz, CDCl₃) δ 8.31 (d, *J* = 1.3 Hz, 1H), 7.73 (d, *J* = 1.3 Hz, 1H), 7.55 – 7.47 (m, 3H), 7.37 – 7.33 (m, 2H), 7.15 (dd, *J* = 8.4, 7.3 Hz, 1H), 5.46 – 5.40 (m, 1H), 5.06 (s, 2H), 1.73 (d, *J* = 6.5 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 166.22, 147.55, 142.10, 139.96, 135.27, 130.18, 129.01, 128.97, 128.91, 127.44, 127.18, 126.72, 103.48, 79.28, 69.84, 20.22; HRMS (ESI): *m/z* calcd for C₁₈H₁₅INO [M+H]⁺; 388.0198, found: 388.0199.


Synthesis of (*R*)-3,5-dimethyl-9-phenyl-1,3-dihydrofuro[3,4-*b*]quinoline (**3s**).




Following the general procedure **D**, **1i** (250 mg, 1.32 mmol) in acetonitrile was allowed to react with Ortho-toluidine (**2g**) (141 mg, 1.32 mmol) in the presence of Cu(OTf)₂ (22 mg, 0.06 mmol), Oxone (405 mg, 1.32 mmol), to afford

compound **3s** in 52% yield (190 mg); Yellow Viscous liquid; ^1H NMR (500 MHz, CDCl_3) δ 7.57 (d, 1H), 7.55 – 7.44 (m, 4H), 7.38 – 7.35 (m, 2H), 7.35 – 7.30 (m, 1H), 5.39 (q, $J = 6.5$ Hz, 1H), 5.06 (s, 2H), 2.86 (s, 3H), 1.70 (d, $J = 6.5$ Hz, 3H). ^{13}C NMR (126 MHz, CDCl_3) δ 163.73, 137.24, 136.26, 129.37, 129.02, 128.83, 128.61, 128.53, 126.16, 125.88, 123.71, 79.39, 69.95, 20.35, 18.49; HRMS (ESI): m/z calcd for $\text{C}_{19}\text{H}_{18}\text{NO}$ $[\text{M}+\text{H}]^+$; 276.1388, found: 276.1390.


Synthesis of methyl (*R*)-4-(5-iodo-3-methyl-1,3-dihydrofuro[3,4-*b*]quinolin-9-yl)benzoate (**3t**).


 Following the general procedure **D**, **1i** (150 mg, 0.6 mmol) in acetonitrile was allowed to react with 2-Iodo aniline (**2c**) (130 mg, 0.6 mmol) in the presence of $\text{Cu}(\text{OTf})_2$ (11.0 mg, 0.03 mmol), Oxone (184 mg, 0.6 mmol), to afford compound **3t** in 55% yield (200 mg); Yellowish oil; ^1H NMR (500 MHz, CDCl_3) δ 8.32 (d, $J = 1.2$ Hz, 1H), 8.24 – 8.17 (m, 2H), 7.64 (d, $J = 1.3$ Hz, 1H), 7.46 – 7.42 (m, 2H), 7.16 (dd, $J = 8.4, 7.3$ Hz, 1H), 5.45 – 5.37 (m, 1H), 5.03 (d, $J = 1.0$ Hz, 2H), 3.97 (s, 3H), 1.72 (d, $J = 6.5$ Hz, 3H). ^{13}C NMR (126 MHz, CDCl_3) δ 166.57, 166.27, 147.66, 140.74, 140.06, 139.99, 130.71, 130.26, 130.09, 129.13, 127.69, 126.63, 126.26, 103.89, 79.26, 69.65, 52.50, 20.15; HRMS (ESI): m/z calcd for $\text{C}_{20}\text{H}_{17}\text{INO}_3$ $[\text{M}+\text{H}]^+$; 446.0253, found: 446.0255.

Synthesis of methyl (*R*)-4-(5-iodo-3,7-dimethyl-1,3-dihydrofuro[3,4-*b*]quinolin-9-yl)benzoate **3u**.


 Following the general procedure **D**, **1i** (150 mg, 0.6 mmol) in acetonitrile was allowed to react with 4-Amino-3-iodotoluene (**2d**) (140 mg, 0.6 mmol) in the presence of $\text{Cu}(\text{OTf})_2$ (11.0 mg, 0.03 mmol), Oxone (184 mg, 0.6 mmol), to afford compound **3u** in 64% yield (178 mg); Yellowish oil; ^1H NMR (500 MHz, CDCl_3) δ 8.22 – 8.19 (m, 2H), 8.18 (d, $J = 1.8$ Hz, 1H), 7.45 – 7.41 (m, 2H), 7.36 (dq, $J = 1.9, 1.0$ Hz, 1H), 5.40 (q, $J = 6.5$ Hz, 1H), 5.00 (d, $J = 1.0$ Hz, 2H), 3.97 (s, 3H), 2.38 (s, 3H), 1.71 (d, $J = 6.5$ Hz, 3H). ^{13}C NMR (126 MHz, CDCl_3) δ 166.63, 165.28, 146.20, 142.01, 140.20, 140.05, 137.88, 130.63, 130.25, 130.01, 129.12, 126.34, 125.26, 103.50, 79.20, 69.67, 52.48, 21.20, 20.18; HRMS (ESI): m/z calcd for $\text{C}_{21}\text{H}_{19}\text{INO}_3$ $[\text{M}+\text{H}]^+$; 460.0409, found: 460.0410.


Synthesis of (*R*)-5-iodo-3-methyl-9-(thiophen-2-yl)-1,3-dihydrofuro[3,4-*b*]quinoline (**3v**).


 Following the general procedure **D**, **1i** (150 mg, 0.85 mmol) in acetonitrile was allowed to react with 2-Iodo aniline (**2c**) (185 mg, 0.85 mmol) in the presence of


Cu(OTf)₂ (15.0 mg, 0.04 mmol), Oxone (262 mg, 0.85 mmol), to afford compound **3v** in 39% yield (130 mg); Yellowish oil; mp 207 °C; ¹H NMR (500 MHz, CDCl₃) δ 8.32 (d, *J* = 1.3 Hz, 1H), 8.08 (dd, *J* = 8.4, 1.3 Hz, 1H), 7.56 (d, *J* = 1.3 Hz, 1H), 7.24 – 7.18 (m, 3H), 5.46 – 5.38 (m, 1H), 5.25 – 5.15 (m, 2H), 1.72 (d, *J* = 6.5 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 166.15, 147.80, 140.03, 135.12, 134.86, 130.92, 129.42, 127.83, 127.67, 127.22, 126.54, 103.82, 79.36, 70.41, 20.19, -17.30; HRMS (ESI): *m/z* calcd for C₁₆H₁₃INOS [M+H]⁺; 393.9762, found: 393.9763.

Synthesis of Lactone (4a-b)

Synthesis of 5-bromo-9-phenylfuro[3,4-*b*]quinolin-1(3H)-one **4a**.



 Following the general procedure **E**, **3c** (200 mg, 0.61 mmol) in benzene was allowed to react with Pyridinium Dichromate (40 mg, 0.12 mmol) and tert-butyl hydroperoxide (0.01 ml, 0.12 mmol), to afford compound **4a** in 67% yield (140 mg); Pale yellowish solid; mp 227 °C; ¹H NMR (500 MHz, CDCl₃) δ 8.23 (dd, *J* = 7.4, 1.3 Hz, 1H), 7.88 (dd, *J* = 8.5, 1.3 Hz, 1H), 7.62 – 7.53 (m, 3H), 7.47 – 7.38 (m, 3H), 5.53 (s, 2H). ¹³C NMR (126 MHz) δ 167.69, 164.67, 152.53, 148.35, 140.01, 136.30, 129.92, 129.19, 128.84, 128.29, 128.24, 127.56, 124.80, 114.28, 69.87; HRMS (ESI): *m/z* calcd for C₁₇H₁₁NO₂ [M+H]⁺; 338.9894, found: 339.9968.

Synthesis - of 5-iodo-9-phenyl-7-(trifluoromethyl)furo[3,4-*b*]quinolin-1(3H)-one (**4b**).

 Following the general procedure **E**, **3f** (260 mg, 0.58 mmol) in benzene was allowed to react with Pyridinium Dichromate (44.33 mg, 0.11 mmol) and tert-butyl hydroperoxide (0.01 ml, 0.11 mmol), to afford compound **4b** in 78% yield (210 mg); White solid; mp 187 °C; ¹H NMR (500 MHz, CDCl₃) δ 8.65 (d, *J* = 1.9 Hz, 1H), 8.19 (dd, *J* = 1.8, 1.0 Hz, 1H), 7.66 – 7.59 (m, 3H), 7.44 – 7.40 (m, 2H), 5.56 (s, 2H). ¹⁹F NMR (471 MHz, CDCl₃) δ -62.38. ¹³C NMR (126 MHz, CDCl₃) δ 166.91, 166.85, 153.33, 151.18, 138.62, 130.44, 130.35 (q, 4.5 Hz) 130.21, 130.08, 129.91 (q, 32 Hz) 128.75 (q, 270 Hz) 126.76, 126.66 (q, 3.2 Hz) 115.42, 104.24, 69.81; HRMS (ESI): *m/z* calcd for C₁₈H₁₀NO₂F₃I [M+H]⁺; 455.9708, found: 455.9703.



Compound S_{2b}, ¹H NMR, CDCl₃, 400 MHz

VK-430(N)
single_pulse



Compound S_{2b}, ¹³C NMR, CDCl₃, 101 MHz



VK-430(N)
single_pulse decoupled gated NOE



Spectral (¹H and ¹³C) Data of Sonogashira Coupling Products (S_{3a-l}).



Compound S_{3a}, ¹H NMR, CDCl₃, 400 MHz

141.1.1.1r





Compound S_{3a}, ¹³C NMR, CDCl₃, 101 MHz

141.2.1.1r





Compound S_{3b}, ¹H NMR, CDCl₃, 400 MHz

138 and 109.5.1.1r





Compound S_{3b}, ¹³C NMR, CDCl₃, 101 MHz

138 and 109.6.1.1r



Compound S_{3c}, ¹H NMR, CDCl₃, 400 MHz

INPROTICS-AV NEO 400-20240702-214610-2485.1.1.1r
1H



Compound S_{3c}, ¹³C NMR, CDCl₃, 101 MHz

INPROTICS-AV NEO 400-20240702-214610-2485.3.1.1r
13C



138.03
132.36
129.45
128.83
128.22
122.26

86.75
84.40

71.18



61.84
59.23

21.20



Compound S_{3d}, ¹H NMR, CDCl₃, 400 MHz



137 and 108.1.1.1r



Compound $\text{S}_{3\text{d}}$, ^{13}C NMR, CDCl_3 , 101 MHz



137 and 108.2.1.1r

138.72
131.68
129.09
119.36
86.69
84.08
71.20
61.82
59.28
21.50




Compound $\text{S}_{3\text{e}}$, ^1H NMR, CDCl_3 , 400 MHz

150.7.1.1r





Compound S_{3e}, ¹³C NMR, CDCl₃, 101 MHz

150.8.1.1r





Compound S_{3f}, ¹H NMR, CDCl₃, 400 MHz

INPROTICS-AV NEO 400-20240710-125350-2485.1.1.1r
1H





Compound S_{3f}, ¹³C NMR, CDCl₃, 101 MHz

INPROTICS-AV NEO 400-20240710-125350-2485.3.1.1.1r
13C



Compound S_{3g}, ¹H NMR, CDCl₃, 400 MHz



VK-390
single_pulse



Compound S_{3g}, ¹³C NMR, CDCl₃, 101 MHz



VK-390
single_pulse decoupled gated NOE

162.33 153.44 136.79 135.03 129.81 128.56 125.79 120.85 104.37 72.55 69.38 61.89





Compound S_{3h}, ¹H NMR, CDCl₃, 400 MHz

149.1.1.1r





Compound S_{3h}, ¹³C NMR, CDCl₃, 101 MHz

149.2.1.1r





Compound S_{3j}, ¹H NMR, CDCl₃, 400 MHz

AV-500-20240905-193026-45590.1.1.1r
1H





Compound S_{3j}, ¹³C NMR, CDCl₃, 101MHz

AV-500-20240905-193026-45590.3.1.1r
13C





Compound S_{3j}, ¹H NMR, CDCl₃, 500 MHz

vk-438
single_pulse





Compound S_{3j}, ¹³C NMR, CDCl₃, 126 MHz

VK-438
single pulse decoupled gated NOE





Compound S_{3k}, ¹H NMR, CDCl₃, 400 MHz

Vk-451
single_pulse





Compound S_{3k}, ¹³C NMR, CDCl₃, 101MHz

Vk-451
single pulse decoupled gated NDE





Compound S₃₁, ¹H NMR, CDCl₃, 500 MHz

vk-452
single_pulse



Compound S₃₁, ¹³C NMR, CDCl₃, 126MHz



vk-452
single_pulse decoupled gated NOE



Spectral (¹H, ¹³C and ¹⁹F) Data of Dihydrofuroquinolines (3a-v)

Compound 3a, ¹H NMR, CDCl₃, 500 MHz



VK-165(D)
single_pulse



Compound 3a, ¹³C NMR, CDCl₃, 126 MHz



VK-165(D)
single pulse decoupled gated NOE

162.30 148.82 141.43 135.64 129.31 129.19 128.96 128.76 128.56 126.46 126.15 125.82 73.16 71.90




Compound 3b, ¹H NMR, CDCl₃, 500 MHz

VK-435
single_pulse





Compound 3b, ¹³C NMR, CDCl₃, 126 MHz

VK-435
single_pulse decoupled gated NOE





Compound 3c, ¹H NMR, CDCl₃, 400 MHz

EXT40524.60.1.1r
Signature SIF VIT VELLORE
CUSBVK177





Compound 3c, ¹³C NMR, CDCl₃, 101 MHz

EXT40524
Signature SIF VIT VELLORE
CUSBVK177





Compound 3d, ¹H NMR, CDCl₃, 400 MHz

EXT40524.90.1.1r
Signature SIF VIT VELLORE
CUSBVK171





Compound 3d, ¹³C NMR, CDCl₃, 101 MHz

EXT40524
Signature SIF VIT VELLORE
CUSBVK171





Compound 3e, ¹H NMR, CDCl₃, 500 MHz

EXT40524.93.1.1r
Signature SIF VIT VELLORE
CUSBVK172





Compound 3e, ¹³C NMR, CDCl₃, 126 MHz

vk-172
single pulse decoupled gated NOE





Compound 3f, ¹H NMR, CDCl₃, 400 MHz

EXT40524.27.1.1r
Signature SIF VIT VELLORE
CUSBVK173



Compound 3f, ¹³C NMR, CDCl₃, 101 MHz



EXT40524
Signature SIF VIT VELLORE
CUSBVK173



Compound 3f, ^{19}F NMR, CDCl_3 , 471 MHz



VK-173
-19F

-62.07





Compound 3g, ¹H NMR, CDCl₃, 400 MHz

CUSB-VK-121.10.1.1r
CUSB-VK-121





Compound 3g, ¹³C NMR, CDCl₃, 101 MHz

VK-121
single pulse decoupled gated NOESY





Compound 3h, ¹H NMR, CDCl₃, 400 MHz

CUSB-VK-122.10.1.1r
CUSB-VK-122





Compound 3h, ¹³C NMR, CDCl₃, 101 MHz

CUSB-VK-122
CUSB-VK-122





Compound 3i, ¹H NMR, CDCl₃, 400 MHz

CUSB-VK-116.10.1.1r
CUSB-VK-116





Compound 3i, ¹³C NMR, CDCl₃, 101 MHz


CUSB-VK-116
CUSB-VK-116



Compound 3j, ¹H NMR, CDCl₃, 400 MHz





Compound 3j, ¹³C NMR, CDCl₃, 101 MHz





Compound 3k, ¹H NMR, CDCl₃, 400 MHz

EXT40524.7.1.1r
Signature SIF VIT VELLORE
CUSBVK198-LS





Compound 3k, ¹³C NMR, CDCl₃, 101 MHz

EXT40524
Signature SIF VIT VELLORE
CUSBVK198-US





Compound 3l, ¹H NMR, CDCl₃, 400 MHz

EXT40524.33.1.1r
Signature SIF VIT VELLORE
CUSBVK199-US





Compound 3l, ¹³C NMR, CDCl₃, 101MHz

EXT40524
Signature SIF VIT VELLORE
CUSBVK199-US





Compound 3m, ¹H NMR, CDCl₃, 500 MHz

VK-191
single_pulse



Compound 3m, ¹³C NMR, CDCl₃, 126 MHz



VK-191
single pulse decoupled gated NMR



Compound 3m, ^{19}F NMR, CDCl_3 , 471 MHz



VK-191
-19F

0.00



Compound 3n, ¹H NMR, CDCl₃, 400 MHz

EXT40524.5.1.1r
Signature SIF VIT VELLORE
CUSBVK187



Compound 3n, ¹³C NMR, CDCl₃, 101MHz



EXT40524
Signature SIF VIT VELLORE
CUSBK187

162.53
146.34
142.06
137.81
135.12
134.16
130.84
129.46
127.75
126.84
125.56

102.88



73.21
72.22

21.19





Compound 3o, ¹H NMR, CDCl₃, 500 MHz

vk-362
single_pulse





Compound 3o, ¹³C NMR, CDCl₃, 126 MHz

VK-362
single pulse decoupled gated NMR




Compound 3p, ¹H NMR, CDCl₃, 500 MHz

VK-363
single_pulse





Compound 3p, ^{13}C NMR, CDCl_3 , 126 MHz

VK-363
single pulse decoupled gated NMR




Compound 3q, ^{13}C NMR, CDCl_3 , 126 MHz

VK-366(U)
single_pulse





Compound 3q, ¹³C NMR, CDCl₃, 126 MHz

VK-366(U)
single pulse decoupled gated



Compound 3r, ¹H NMR, CDCl₃, 500 MHz



Vk-443
single_pulse



Compound 3r, ¹³C NMR, CDCl₃, 126 MHz



Vk-443

single pulse decoupled gated
NOE





Compound 3s, ¹H NMR, CDCl₃, 500 MHz

VK-444
single_pulse





Synthesis of 3s. ¹³C NMR, CDCl₃, 126 MHz

VK-444
single pulse decoupled gated NOE





Synthesis of 3t. ¹H NMR, CDCl₃, 500 MHz

VK-456
single_pulse





Compound 3t, ¹³C NMR, CDCl₃, 126 MHz

VK-456
single pulse decoupled gated NMR



Compound 3u, ¹H NMR, CDCl₃, 500 MHz



VK-455
single_pulse



Compound 3u, ¹³C NMR, CDCl₃, 126MHz



VK-455

single pulse decoupled gated NOE




Compound 3v, ¹H NMR, CDCl₃, 500 MHz

VK-454
single_pulse





Compound 3v, ¹³C NMR, CDCl₃, 126 MHz

VK-454
single_pulse decoupled gated NOE



Compound 4a, ^1H NMR, CDCl_3 , 500 MHz

Vk-428
single_pulse



Compound 4a, ^{13}C NMR, CDCl_3 , 126 MHz

VK-340(u)

single pulse decoupled gated NOESY

166.69
166.67

152.53

148.35

140.01

136.30

129.92

129.19

128.84

128.29



128.24

127.56

124.80

114.28



69.87



Compound 4b, ^{19}F NMR, CDCl_3 , 471 MHz

CUSB-VK-427
-19F

-62.38



Sample Preparation and Crystal Structure Description

The pure compound **4a** as obtained from column chromatography was crystallized from a mixture solvent of hexanes and ethyl acetate (9:1). Compound **4a** crystallizes in the triclinic crystal system with a centrosymmetric $P\bar{1}$ space group. The molecular structure of **4a** is shown in Fig. 1, and the crystallographic data and refinement parameters are listed in Table S1 (ESI†). The molecular geometry is defined by characteristic bond lengths, including C11–O2 (1.192 Å), C11–O1 (1.372 Å), C1–O1 (1.446 Å), C2–N1 (1.303 Å), C3–N1 (1.369 Å), and C4–Br1 (1.883 Å). Key bond angles such as O2–C11–O1 (120.3°), C11–O1–C1 (111.53°), C2–N1–C3 (114.80°), C3–C4–Br1 (118.62°), and C5–C4–Br1 (119.59°) are consistent with the expected bonding environment and confirm the structural integrity of the molecule in the solid state.




Figure S1: ORTEP diagram of compound **4a** at 50% thermal ellipsoid probability.

Data availability

The crystallographic data for compound **4a** have been deposited with the Cambridge Crystallographic Data Centre (CCDC) under deposition number **2519622** and can be obtained from the CCDC via their website: <https://www.ccdc.ac.uk/structures>.

Method

X-ray crystallography

Single-crystal X-ray diffraction data were collected on a Rigaku XtaLAB Synergy-I diffractometer using *CrysAlisPro* software, with graphite-monochromated Mo K α ($\lambda = 0.71073$ Å) and Cu K α ($\lambda = 1.54184$ Å) radiation at 293 K. The crystal structures were solved using the SHELXL-97 program implemented in OLEX2.0, and refined by full-matrix least-squares procedures on F^2 . Anisotropic displacement parameters were applied to all non-hydrogen atoms.^{3,4} Hydrogen atoms were placed in calculated positions and refined using a riding model with idealized geometries. Structural visualization and analysis were carried out using Mercury software for Windows.

Table S1: Crystal data and structure refinement for compound 4a.

Parameters	Compound 4a
CCDC	2519622
Empirical formula	C ₁₇ H ₁₀ BrNO ₂
Formula weight	340.17
Temperature/K	293
Crystal system	Triclinic
Space group	P-1
a/Å	6.94070(10)
b/Å	10.10700(10)
c/Å	10.61130(10)
α /°	79.6910(10)
β /°	77.5300(10)

$\gamma/^\circ$	71.1550(10)
Volume/ \AA^3	683.038(14)
Z	2
$\rho_{\text{calc}}/\text{cm}^3$	1.654
μ/mm^{-1}	4.133
F(000)	340.0
Crystal size/ mm^3	$0.26 \times 0.24 \times 0.15$
Radiation	Cu K α ($\lambda = 1.54184$)
2Θ range for data collection/ $^\circ$	8.594 to 136.16
Index ranges	$-8 \leq h \leq 8, -12 \leq k \leq 12, -12 \leq l \leq 11$
Reflections collected	13242
Independent reflections	2474 [$R_{\text{int}} = 0.0286, R_{\text{sigma}} = 0.0164$]
Data/restraints/parameters	2474/0/191
Goodness-of-fit on F^2	1.047
Final R indexes [$I \geq 2\sigma(I)$]	$R_1 = 0.0294, wR_2 = 0.0767$
Final R indexes [all data]	$R_1 = 0.0307, wR_2 = 0.0779$
Largest diff. peak/hole / $e \text{\AA}^{-3}$	0.40/-0.56

Table S2: Bond Lengths for compound 4a.

Atoms		Length/ \AA	Atoms		Length/ \AA
Br ¹	C ⁴	1.883(2)	C ¹⁰	C ¹¹	1.478(3)
O ¹	C ¹¹	1.372(3)	C ⁷	C ⁶	1.362(3)
O ¹	C ¹	1.446(3)	C ⁹	C ¹²	1.484(3)
O ²	C ¹¹	1.192(3)	C ⁴	C ⁵	1.364(3)
N ¹	C ³	1.369(3)	C ¹²	C ¹⁷	1.385(3)

N ¹	C ²	1.303(3)	C ¹²	C ¹³	1.395(3)
C ³	C ⁸	1.431(3)	C ²	C ¹	1.493(3)
C ³	C ⁴	1.417(3)	C ⁵	C ⁶	1.396(3)
C ⁸	C ⁷	1.418(3)	C ¹⁷	C ¹⁶	1.398(4)
C ⁸	C ⁹	1.432(3)	C ¹³	C ¹⁴	1.374(4)
C ¹⁰	C ⁹	1.381(3)	C ¹⁶	C ¹⁵	1.375(5)
C ¹⁰	C ²	1.399(3)	C ¹⁴	C ¹⁵	1.366(5)

Table S3: Bond Angles for compound 4a.

Atoms			Angle/°	Atoms			Angle/°
C ¹¹	O ¹	C ¹	111.53(17)	C ¹⁷	C ¹²	C ⁹	121.7(2)
C ²	N ¹	C ³	114.80(18)	C ¹⁷	C ¹²	C ¹³	119.2(2)
N ¹	C ³	C ⁸	123.63(19)	C ¹³	C ¹²	C ⁹	119.1(2)
N ¹	C ³	C ⁴	118.44(19)	N ¹	C ²	C ¹⁰	126.86(19)
C ⁴	C ³	C ⁸	117.93(19)	N ¹	C ²	C ¹	124.17(19)
C ³	C ⁸	C ⁹	118.79(18)	C ¹⁰	C ²	C ¹	108.96(19)
C ⁷	C ⁸	C ³	118.84(19)	O ¹	C ¹¹	C ¹⁰	107.77(18)
C ⁷	C ⁸	C ⁹	122.34(19)	O ²	C ¹¹	O ¹	120.3(2)
C ⁹	C ¹⁰	C ²	120.30(19)	O ²	C ¹¹	C ¹⁰	132.0(2)
C ⁹	C ¹⁰	C ¹¹	132.1(2)	C ⁴	C ⁵	C ⁶	119.6(2)
C ²	C ¹⁰	C ¹¹	107.54(18)	C ⁷	C ⁶	C ⁵	121.4(2)
C ⁶	C ⁷	C ⁸	120.4(2)	C ¹²	C ¹⁷	C ¹⁶	119.6(3)
C ⁸	C ⁹	C ¹²	122.23(18)	C ¹⁴	C ¹³	C ¹²	120.2(3)

C ¹⁰	C ⁹	C ⁸	115.61(19)	O ¹	C ¹	C ²	104.19(18)
C ¹⁰	C ⁹	C ¹²	122.16(19)	C ¹⁵	C ¹⁶	C ¹⁷	120.1(3)
C ³	C ⁴	Br ¹	118.62(16)	C ¹⁵	C ¹⁴	C ¹³	120.7(3)
C ⁵	C ⁴	Br ¹	119.59(17)	C ¹⁴	C ¹⁵	C ¹⁶	120.2(3)
C ⁵	C ⁴	C ³	121.8(2)				

References

1. (a) V. Kumar, A. Dey, R. K. Maurya, M. Kumari and M. Khatravath, *ChemistrySelect*, 2025, **10**, 202501315; (b) Z. Yu, L. Liu and J. Zhang, *Chem. Eur. J.*, 2016, **22**, 8488–8492; (c) M. Yang, X. Wang and J. Zhao, *ACS Catal.*, 2020, **10**, 5230–5235; (d) M. Berthet, O. Songis, C. Taillier and V. Dalla, *J. Org. Chem.*, 2017, **82**, 9916–9922.
2. S. Nakamura, M. Sayama, A. Uwamizu, S. Jung, M. Ikubo, Y. Otani, K. Kano, J. Omi, A. Inoue, J. Aoki and T. Ohwada, *J. Med. Chem.*, 2020, **63**, 9990–10029.
3. G. M. Sheldrick, *Acta Cryst.*, 2015, **C71**, 3–8.
4. O. V. Dolomanov, L. J. Bourhis, R. J. Gildea, J. A. K. Howard, and H. Puschmann, *J. Appl. Cryst.*, 2009, **42**, 339–341.